Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned an average rating of “Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $19.43.

Several analysts have weighed in on the company. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, HC Wainwright increased their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th.

Replimune Group Stock Up 4.7 %

Replimune Group stock opened at $7.99 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a 50-day simple moving average of $10.85 and a 200-day simple moving average of $11.78. The firm has a market capitalization of $615.35 million, a P/E ratio of -2.60 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Boxer Capital Management LLC acquired a new stake in Replimune Group during the fourth quarter valued at approximately $21,754,000. Tang Capital Management LLC lifted its position in shares of Replimune Group by 125.0% during the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after acquiring an additional 1,500,000 shares during the last quarter. State Street Corp boosted its stake in shares of Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock worth $132,761,000 after acquiring an additional 1,083,633 shares in the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of Replimune Group in the 4th quarter worth $11,504,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.